AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), broke ground on a new facility at its Copenhagen, Denmark site. This multipurpose facility will include a manufacturing building, an office building and a visitors center. The manufacturing building will be comprised of four levels holding approximately 8,000 square meters distributed across manufacturing, quality control laboratories, technical and warehouse areas. Around 250-300 new jobs will be created as a result of the expansion. Production will be based on genetically modified organisms, biosafety level 1, manufactured with single-use technology in clean rooms.
 
The biopharmaceuticals CDMO market continues to grow in double digits annually and the expansion allows AGC Biologics to strengthen its market position. This investment will more than double AGC Biologics’ single-use bioreactor mammalian cell-culture capacity in Copenhagen. AGC’s other biologics facilities are in Seattle WA, Boulder CO and Chiba, Japan.
 
“We are excited to announce the groundbreaking of the new facility,” said Patricio Massera, CEO, AGC Biologics. “We are fully committed to understand and meet our customers’ needs, as we continuously seek to provide new capacity and new services.”
 
Andrea C. Porchia, Copenhagen site head, AGC Biologics, said, “We are now establishing a new state-of-the-art facility with a flexible and efficient set-up for biologic drug substance manufacturing. It will be a great facility and we are looking forward to making it available for existing and new customers.”